StockNews.com Begins Coverage on Adaptimmune Therapeutics (NASDAQ:ADAP)

Research analysts at StockNews.com began coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a research note issued on Saturday. The firm set a “buy” rating on the biotechnology company’s stock.

ADAP has been the subject of several other reports. Guggenheim decreased their price objective on Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating for the company in a research report on Wednesday, March 26th. Scotiabank reduced their price target on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a report on Friday, March 21st. Finally, Wells Fargo & Company lowered their price objective on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a research report on Friday, March 21st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1.93.

Adaptimmune Therapeutics Stock Down 6.4 %

NASDAQ ADAP opened at $0.21 on Friday. The stock has a market capitalization of $52.71 million, a P/E ratio of -0.94 and a beta of 2.52. Adaptimmune Therapeutics has a 52 week low of $0.20 and a 52 week high of $1.55. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. The stock has a fifty day moving average of $0.51 and a 200-day moving average of $0.66.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings data on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. The business had revenue of $3.22 million during the quarter, compared to the consensus estimate of $16.56 million. On average, equities research analysts forecast that Adaptimmune Therapeutics will post -0.14 EPS for the current year.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Two Seas Capital LP bought a new position in shares of Adaptimmune Therapeutics in the 4th quarter valued at $7,992,000. Long Focus Capital Management LLC grew its position in Adaptimmune Therapeutics by 54.1% in the fourth quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company’s stock valued at $11,040,000 after acquiring an additional 7,194,503 shares during the last quarter. Renaissance Technologies LLC grew its position in Adaptimmune Therapeutics by 52.5% in the fourth quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company’s stock valued at $1,361,000 after acquiring an additional 869,949 shares during the last quarter. Jane Street Group LLC raised its stake in Adaptimmune Therapeutics by 87.7% during the fourth quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company’s stock worth $176,000 after acquiring an additional 152,780 shares in the last quarter. Finally, LPL Financial LLC lifted its holdings in shares of Adaptimmune Therapeutics by 106.5% in the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 94,623 shares during the last quarter. 31.37% of the stock is currently owned by institutional investors and hedge funds.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.